Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Sues FDA For Inaction On Omnitrope NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”
Advertisement

Related Content

Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA
FDA Must Take Action On Sandoz' Omnitrope Application, U.S. District Court says
Sandoz Omnitrope Gains First “Similar Biological” Positive Opinion In the EU
FDA “Unable” To Act On Hylenex By User Fee Deadline
FDA Approps Bill Debate Could Include “Controversial Amendments,” Sen. Hatch Says
Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
FDA Makes It Official: Action On Human Growth Hormone Will Wait
FDA Makes It Official: Action On Human Growth Hormone Will Wait
Pfizer Petitions FDA To Deny Sandoz Omnitrope NDA; Test Case For Follow-On Biologics

Topics

Advertisement
UsernamePublicRestriction

Register

PS062882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel